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Viruses initiate infection by attaching to molecules or recep-
tors at the cell surface. Hepatitis C virus (HCV) enters cells via a
multistep process involving tetraspanin CD81, scavenger recep-
tor class B member I, and the tight junction proteins Claudin-1
and Occludin. CD81 and scavenger receptor class B member I
interact with HCV-encoded glycoproteins, suggesting an initial
role in mediating virus attachment. In contrast, there are mini-
mal data supporting Claudin-1 association with HCV particles,
raising questions as to its role in the virus internalization proc-
ess. In the present study we demonstrate a relationship between
receptor active Claudins and their association and organization
with CD81 at the plasma membrane by fluorescence resonance
energy transfer and stoichiometric imaging methodologies.
Mutation of residues 32 and 48 in the Claudin-1 first extracel-
lular loop ablates CD81 association and HCV receptor activity.
Furthermore, mutation of the same residues in the receptor-
inactive Claudin-7 molecule enabled CD81 complex formation
and virus entry, demonstrating an essential role for Claudin-
CD81 complexes in HCV infection. Importantly, Claudin-1
associated with CD81 at the basolateral membrane of polarized
HepG2 cells, whereas tight junction-associated pools of Clau-
din-1 demonstrated a minimal association with CD81. In sum-
mary, we demonstrate an essential role for Claudin-CD81 com-
plexes in HCV infection and their localization at the basolateral
surface of polarized hepatoma cells, consistent with virus entry
into the liver via the sinusoidal blood and association with basal
expressed forms of the receptors.
Hepatitis CVirus (HCV)3 poses a global health problem,with
over 170 million infected individuals worldwide, and estab-
lishes a persistent infection in the majority of individuals that
leads to progressive liver injury, frequently culminating in
fibrosis and hepatocellular carcinoma. The major cell types
supporting HCV replication in vivo are hepatocytes in the liver.
The observation, that retroviral pseudoparticles bearing HCV
E1E2 glycoproteins (HCVpp) infect hepatocytes and hepatoma
derived cell lines, suggests that virus glycoprotein-receptor
interactionsmay in part defineHCV tropism for the liver (1–3).
Inhibiting HCV entry into host cells is one obvious target for
therapeutic intervention, and the recent development of HCV
strains that replicate and assemble infectious particles in cul-
tured cells (4–6) has allowed studies on HCV particle internal-
ization and replication.
Current evidence suggests that CD81 (1, 2, 7–9), scavenger
receptor class B member I (10–13), and tight junction proteins
Claudin-1 (CLDN1) (14–17) and Occludin (18–20) are critical
factors defining HCV entry (reviewed in Ref. 21). Two addi-
tionalClaudin familymembers, CLDN6andCLDN9, have been
reported to confer HCVpp entry (15, 17). CD81 and scavenger
receptor class B member I interact with HCV-encoded E1E2
glycoproteins (gps), suggesting an initial role in mediating high
affinity virus attachment to the cell (reviewed in Ref. 22). In
contrast, there is minimal data supporting an interaction of
CLDN1 with the HCV particle that may reflect the multistep
and sequential nature of the entry process or that tight junction
proteins facilitate particle internalization by indirect routes.
CD81 is a member of the tetraspanin superfamily of type III
transmembrane proteins that contain four transmembrane
domains and several conserved signature amino acid residues,
including a conserved CCG motif and 4–6 cysteine residues
that form critical disulfide bonds in the second extracellular
loop (EC2). Tetraspanins associate with tetraspanin and non-
tetraspanin proteins at cholesterol enrichedmicrodomains and
exert an array of biological functions, including cell-cell adhe-
sion, cell migration, and proliferation (reviewed in Ref. 23).
CD81 interacts with HCV-encoded E2 glycoprotein via a series
of discontinuous amino acid residues in EC2 (1, 2, 7–9, 24).
Kitadokoro and colleagues reported on the dimeric structure of
CD81 EC2, suggesting that motifs within this domain drive
CD81 dimerization (24, 25). CD81 is known to associate with
the related tetraspanin CD9 and the immunoglobulin super-
family proteins EWI-2 and EWI-F (26), however, the one or
more mechanisms underlying these protein-protein interac-
tion(s) are unknown.
CLDNs are critical components of tight junctions that regu-
late paracellular permeability of endothelia and epithelia (27).
Although CLDN polymerization is critical for the establish-
ment of membranous tight junction strands (28), additional
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transmembrane (Occludin, tricellulin, and junctional adhesion
molecule) and scaffold proteins are required for the spatial and
functional organization of tight junctions in polarized epithelia
(reviewed in Ref. 29). CLDNs exhibit a similar topology to the
tetraspanins and have the capacity to associate with themselves
and other CLDNs both within a cell and between apposing cells
via interactions between their extracellular loops (27, 28).
Piontek and colleagues recently reported FRET between tagged
forms of CLDN5, suggesting that dimers are the primary build-
ing block(s) of tight junction strands (28).
We (30) and others (16, 31, 32) have reported that CLDN1
associates with CD81 in a variety of cell types. To ascertain the
role of CLDN1-CD81 complexes inHCV entry, we investigated
the relationship between various members of the CLDN family
and CD81 in 293T human embryonal kidney (HEK) cells. Only
CLDNs 1, 6, 9, and 12 co-localized with CD81 in a defined
organization at the plasma membrane, consistent with a 1:1
molar relationship or stoichiometry. FRET studies confirmed
interaction(s) between CLDN1, -6, and -9 and CD81, suggest-
ing a relationship between CLDN association with CD81 and
HCV receptor activity. In contrast, several members of the
CLDN family associated with Occludin independent of viral
receptor activity. Previous studies have highlighted a critical
role for the first extracellular loop (EC1) of CLDN1 in HCV
entry (14–17). Mutation of residues 32 and 48 in CLDN1 EC1
ablated its association with both CD81 and Occludin and viral
receptor activity. Importantly, mutation of the same residues in
the receptor inactive CLDN7 molecule allowed association
with CD81 and facilitated viral entry into 293T cells in the
absence of any detectable Occludin interaction. These data
demonstrate an essential role for CLDN-CD81 complexes in
HCV infection.
Because CLDNs oligomerize and associate with other cyto-
plasmic and signaling proteins to form tight junctions in polar-
ized cells we investigated the presence and location of CLDN1-
CD81 complexes in polarized HepG2 hepatoma cells. CLDN1
associated with basolateral pools of CD81 in polarized hepa-
toma cells in a comparable manner to that observed in non-
polarized 293T cells. In contrast, CLDN1-CD81 complexes
were absent from apically located tight junctions. The observa-
tion that HCV enters the liver via the sinusoidal blood and will
encounter receptors expressed on the basolateral hepatocyte
surface is consistent with a model where virus engagement of
basolateral pools of CD81 and CLDN1may initiate the particle
internalization process.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents—293T and HepG2 cells were prop-
agated in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and 1% non-essential amino acids.
HepG2 polarity was determined by MRP2 staining as previ-
ously described (33). The primary antibodies used were: anti-
CLDN1, JAY.8 (Invitrogen), and 1C5-D9 (Novus); anti-CD81,
2s20, and 2s66 (University of Birmingham); anti-CD9 and TS9
(Abcam,UK); anti-VAP1 (gift fromDavidAdams, University of
Birmingham); and anti-ZO-1 (Invitrogen). Secondary labeled
antibodies were obtained from Invitrogen: Alexa Fluor 488 goat
anti-mouse IgG, 488 goat anti-mouse IgG2a, 633 goat anti-
mouse IgG, 633 goat anti-mouse IgG1, 488 goat anti-rabbit IgG,
and 633 goat anti-rabbit IgG.
HCVpp Genesis and Infection—Pseudoviruses expressing
luciferase were generated as previously reported (30). Briefly,
293T cells were transfected with a 1:1 ratio of plasmids encod-
ing HIV provirus expressing luciferase and HCV strain H77
E1E2 envelope gps, MLV gp, or empty vector (Env-pp), as pre-
viously described (2). Supernatants were harvested 48 h post
transfection, pooled, and filtered. Virus-containing medium
was added to target cells plated at 1.5  104 cells/cm2 for 4 h,
unbound virus was removed by washing, and the cells were
refed with growth media and incubated at 37 °C. At 72h post-
infection the cells were lysed, the substrate was added, and
luciferase activity was measured for 10 s in a luminometer
(Lumat LB 9507). Specific infectivity was calculated by sub-
tracting the mean Env-pp relative light unit signal from the
HCVpp or MLVpp signals.
Generation of Fluorescence-tagged CLDN Proteins—The
CLDN proteins used in this study were kindly supplied as a
panel of pBABE-CLDN constructs by HongKui Deng (17) and
were fused to Aequorea coerulescens green fluorescent protein
(AcGFP) or Discosoma sp. red-monomer fluorescent (DsRED)
at their N terminus using previously described methods (30).
CLDN1 and CLDN7 mutants were kindly provided by Charles
Rice (14) and amplified using the following primers: 5-GGAT-
CCGCCACCATGGCCAACGCGGGGCTG (CLDN1 FWD),
5-CTCGAGTCACACGTAGTCTTTCCCGCTGG (CLDN1
REV), 5-GGATCCGCCACCATGGCCAATTCGGGCC-
TGCA (CLDN7 FWD), and 5-AAGCTTTCACACATACTC-
CTTGGAAGAGTTGG (CLDN7 REV) with the Phusion High
Fidelity DNA polymerase (New England Biolabs) according to
the manufacturer’s instructions. PCR products were inserted
into the pBABE vector using BamHI/XhoI (CLDN1) or BamHI/
HindIII (CLDN7) restriction sites and sequenced.
Laser Scanning ConfocalMicroscopy—293T andHepG2 cells
transfected to express AcGFP- and DsRED-tagged CLDNs or
CD81 were grown on 13-mm glass coverslips and fixed in ice-
cold methanol. The cells were imaged on a Zeiss Meta head
laser scanning confocal microscope with settings optimized for
each fluorescent protein to obtain the highest signal-to-noise
ratio. Both 63 1.3 numerical aperture (NA) water immersion
and 100  1.4 NA oil immersion objectives were employed to
provide optimal resolution. CLDN and CD81 expression at the
plasma membrane and intracellular locations was quantified
using the overlay, profiling, and intensity frequency tools of
Zeiss laser scanning confocal microscope software. Arbitrary
fluorescence units (AFUs) were calculated by combining the
number of pixels multiplied by the average intensity for the
whole cell and was defined as 100%. The relative fluorescent
intensities at the plasma membrane and intracellular locations
were calculated relative to the whole cell signal.
Antibody Staining—293T cells grown on poly-L-lysine-
coated glass coverslips were fixed in ice-cold methanol for 5
min. Primary antibodies were diluted in PBS/0.5% BSA (PBS-
BSA buffer) and incubated with cells for 1 h at room tempera-
ture. Cells were washed 3 in PBS-BSA before addition of
labeled secondary Abs for a further hour at room temperature.
Finally, cells were washed 3 in PBS-BSA before counterstain-
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ing with 4,6-diamidino-2-phenylindole in PBS for 5 min. Cov-
erslipsweremounted on glass slides for imaging (ProLongGold
Antifade, Invitrogen).
Fluorescence Intensity Ratio Analysis—The AcGFP and
DsRED fluorophores were quantified using the profile function
of theZeiss laser scanning confocalmicroscope software,which
measures the pixel intensity of the two fluorophores along the
cell periphery (30). The brightness or intensity values of each
pixel in the red and green channels were recorded to generate a
series of paired values around the cell periphery. In the case of
HepG2 cells, this series could be stratified according towhether
or not pixels were located at the basolateral membrane or tight
junction, as defined by ZO-1 staining. These paired fluorescent
intensity values were used to generate a scatter plot. The degree
of association between the signals can be described by a simple
linear regression, where the slope y/x (red signal/green signal)
describes the relative fluorescent signal and has been termed
the fluorescence intensity ratio (FIR) (34, 35). The correlation
coefficient (r2) determines how well the data fit the linear
regression slope. Theoretically a 1:1 ratio of proteins would
result in a FIR of 1, but as the absolute intensity of the DsRED
fluorophore is 60% of AcGFP a FIR of 0.6 is consistent with a 1:1
ratio. To confirm this we exchanged the fluorophores fused to
CD81 andCLDN1 andperformed the analysis for both g.CD81/
r.CLDN1- and g.CLDN1/r.CD81-transfected cells. In both
cases similar gradients of 0.6 were obtained for the red and
green fluorophores (data not shown).
FRET—The gradual acceptor photobleaching method of
FRET was used, which entailed photobleaching the DsRED flu-
orophore gradually over timewhilemonitoringAcGFP fluores-
cent intensity, as previously described (30). The profile of
AcGFP- and DsRED-tagged proteins at the plasma membrane
provided up to 1000 pixels for this analysis. After background
and cross-talk correction, any increase in AcGFP intensity fol-
lowing DsRED photobleaching could be ascribed to FRET
between the proteins, implying a distance of10 nm. The per-
cent FRET was defined as the proportion of pixels showing a
measurable increase in AcGFP intensity (30).
Antibody Treatments and Neutralization Assays—293T cells
grown on poly-L-lysine-coated glass coverslips were incubated
with anti-CD81 or controlmonoclonal antibody (mAb) at 37 °C
for 1 h. Cells were fixed immediately in ice-cold methanol with
duplicate samples undergoing secondary antibody staining to
verify primarymAbbinding. Sampleswere counterstainedwith
4,6-diamidino-2-phenylindole (Invitrogen) in PBS for 5 min.
Coverslips were mounted (ProLong Gold Antifade, Invitrogen)
on glass slides, and the cells were imaged with a meta head
confocal microscope (Zeiss, LSM510) and a 100  1.3 NA oil
immersion objective. In parallel, mAb-treated cells were
infected with HCVpp, MLVpp, or Env-pp for 4 h at 37 °C,
unbound virus and agents were removed by washing, and the
cells were cultured for 72h. Viral infection was assessed by
measuring luciferase activity, as previously described (2).
Cholesterol Modifications—293T cells grown on poly-L-ly-
sine-coated glass coverslips were incubated inDulbecco’smod-
ified Eagle’s medium containing 10 mM methyl--cyclodextrin
(MCD, Sigma) for 1 h at 37 °C. Dose-response assays showed
that 10 mMMCD treatment for 1 h removed50% of choles-
terol without affecting cell viability (data not shown). Choles-
terol was partially replenished in the MCD-treated cells by
incubatingwith 1mMMCD-cholesterol complex for 1 h (cho-
lesterol, water-soluble, Sigma). Following these treatments the
cells were fixed immediately in ice-cold methanol, counter-
stained with 4,6-diamidino-2-phenylindole, and mounted.
The cholesterol content before and after the various treatments
was determined using an Amplex Red Assay kit (Invitrogen) in
accordance with the manufacturer’s instructions. In parallel,
MCD-treated cells were infected with HCVpp, MLVpp, or
Env-pp for 4 h at 37 °C, unbound virus and agents were
removed by washing, and the cells were cultured for 72 h. Viral
infection was assessed by measuring luciferase activity, as pre-
viously described (2).
Analysis of CLDN1-CD81 Interactions by Surface Plasmon
Resonance—The first extracellular domain(s) (EC1) of CLDN1
and CLDN7 between amino acid residues 29–81 were con-
structed using overlapping primers, introducing terminal NotI
and SalI restriction sites. The EC1 sequences were cloned into
the pMAL-c2 expression plasmid (New England Biolabs)
downstream of the maltose-binding protein (MBP) sequence
and a triple-alanine linker. Sequences were confirmed by big-
dye terminator sequencing. The proteins were expressed in
BL21(DE3)-competent cells (Stratagene), isolated from the sol-
uble fraction, and batch purified using amylose resin (NewEng-
land Biolabs) as previously described (36). Monomeric MBP-
EC1 fusion proteins were further purified by size-exclusion
chromatography (Superdex 75 26/60, Amersham Biosciences),
and their purity was confirmed by analytical size-exclusion
chromatography (Superdex 75 3.2/30) and SDS-PAGE analysis.
The molecular masses of each protein were confirmed by mass
spectrometry.
Recombinant protein interactions were assessed using a Bia-
core 3000 system (Biacore, Amersham Biosciences). MBP-
CLDN1 EC1 or MBP-CD81 EC2 were immobilized to a CM5
chip using a standard amine-coupling method (Biacore, Amer-
sham Biosciences) and MBP-CLDN1, MBP-CLDN7, MBP-
CD81 and control MBP flowed over the chip surface at 1
mg/ml. To control for nonspecific protein interactions all
recombinant proteins were flowed over an “empty” (activated
1 M ethanolamine-blocked) channel, and any response units
observed were subtracted from test channels. All interactions
were performed in HBS-EP buffer (Biacore, Amersham Bio-
sciences) at 25 °C at a flow rate of 5 l/min for 10 min, and
dissociation was recorded for 2 min.
Statistics—The association between fluorescent proteins was
assessed by linear regression; we chose to use the median and
interquartile range of the values obtained to take into account
the non-Gaussian distribution of the data. The %FRET values
fit a Gaussian distribution and are presented as mean  S.D.
Differences in %FRET observed between samples were com-
pared by Fisher’s exact test. Corrections for multiple sampling
(Bonferroni method and Dunnett’s multiple comparison test)
were used when appropriate. Statistical analyses were carried
out in the Prism 4 package (GraphPad software, San Diego,
CA), and probabilities are represented as p 0.05 (*), p 0.01
(**), and p 0.001 (***).
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RESULTS
Stoichiometry of CLDN1-CD81 Complexes—HEK 293T cells
do not express CLDNs and are the preferred cell type to study
homotypic and heterotypic CLDN interactions (28). Fur-
thermore, expression of exogenous CLDN1 in 293T cells
facilitates HCV entry and replication (14–17, 30). We there-
fore selected 293T cells to study the relationship between
plasma membrane expressed forms of AcGFP- and DsRED-
tagged CLDN1 and CD81. Several reports have quantified
the ratio of fluorescent proteins at defined locations to assess
protein subunit stoichiometry of cyclic nucleotide-gated
channels and epithelial sodium channels in mammalian cells
(34, 35). CD81 has been reported to dimerize (3, 31, 37); we
therefore measured AcGFP.CD81 (g.CD81) and DsRED.CD81
(r.CD81) relative expression at the plasma membrane of ten
individual cells. We observed a significant association between
g.CD81 and r.CD81 AFUs with a median FIR of 0.6 with an
interquartile range (IQR) of 0.58–0.62 (r2 0.5, 0.4–0.5) (Fig.
1A). If one corrects for the 60% lower fluorescence of the
DsRED fluorophore compared with AcGFP, the ratio increases
to 1.0, implying an equimolar association between g.CD81 and
r.CD81, consistent with protein dimerization.
FIGURE 1. Fluorescent intensity ratio of CLDN1andCD81 in 293T cells. 293T cells were transfected to express AcGFP (g) andDsRED (r) fluorescence-tagged
g.CD81-r.CD81 (A); g.CLDN1-r.CD81 (B), or g.CLDN1-r.CLDN1 (C). AcGFP andDsRed arbitrary fluorescence units (AFUs) at the cell peripherywere determinedby
laser scanning confocal microscopy and used to generate a scatter plot, allowing one to calculate a correlation coefficient (r2) and fluorescent intensity ratio
(FIR) for each cell analyzed. A representative scatter plot is depicted in the middle column, and the r2 correlation coefficient (white bars) and FIR (black bars)
values for ten cells are summarized as a bar chart in the final column, where each bar depicts a single cell, and the arrow denotes the respective values for the
presented image and scatter plots. In summary, the median FIR values from analyzing ten cells expressing g.CD81-r.CD81, g.CLDN1-r.CD81, and g.CLDN1-
r.CLDN1 were 0.56 (IQR 0.53–0.59 and r2 0.47 (IQR 0.38–0.51)), 0.68 (IQR 0.63–0.74 and r2 0.45 (IQR 0.39–0.57)), and 0.56 (IQR 0.47–0.64 and r2 0.29 (IQR
0.25–0.42)), respectively.
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Analysis of 293T cells expressing g.CLDN1 and r.CD81 dem-
onstrated a significant association with a median FIR of 0.7
(r2  0.5), suggesting that CLDN1 and CD81 associate in a
similar 1:1 relationship to that seen for g.CD81-r.CD81 (Fig.
1B). A similar relationship was noted for 293T cells co-express-
ing g.CLDN1 and r.CLDN1 (median FIR of 0.6), however a
greater level of heterogeneity was apparent (r2 0.3, IQR 0.3–
0.4), with some cells showing little or no evidence for protein
association (Fig. 1C), possibly reflecting the more dynamic
nature of CLDN1 homotypic associations required during
strand formation (28, 38–41).
We previously reported that FRET occurs between g.CLDN1
and r.CD81 (30), leading to a transfer of energy from donor to
recipient proteins and a concomitant loss in AcGFP fluores-
cencewhich could bias the regression analysis and alter the FIR.
To assess whether FRET altered FIR values, we performed sep-
arate regression analyses for FRET and non-FRET data points.
FRET occurred between CLDN1 and CD81 and had a minimal
effect on FIR (supplemental Fig. S1), consistent with the linear
relationship observed between the fluorescent proteins over a
range of protein expression (AFUs). In summary, quantifica-
tion of fluorescence-tagged proteins has allowed us to define
the stoichiometry of the plasmamembrane-expressed CLDN1-
CD81 receptor complex.
Association of CLDN Family
Members with CD81—To investi-
gate whether other CLDN pro-
teins could associate with CD81
we generated a panel of AcGFP
N-terminal-tagged fusion proteins
representing classic (CLDN4, -6, -7,
-9, -15, and -17) and non-classic
(CLDN11 and -12) members of the
CLDN family. All of the g.CLDN
proteins localized to a comparable
level at the plasma membrane and
demonstrated enhanced expres-
sion at areas of cell-cell contact,
consistent with trans interaction(s)
between CLDNs expressed on adja-
cent cells (data not shown) (28).
HCVpp only infected 293T cells
expressing CLDN1, -6, and -9,
whereas MLVpp infected parental
and CLDN-expressing cells with
comparable efficiency (supplemen-
tal Fig. S2), confirming earlier
reports that a restricted number of
CLDNs support HCV entry (15, 17).
To investigate whether CLDN asso-
ciation with CD81 defines HCV co-
receptor activity we measured the
FIR of g.CLDN-r.CD81 complexes
in co-transfected 293T cells. A sig-
nificant association was observed
between AcGFP and DsRED sig-
nals in cells expressing g.CLDN1,
g.CLDN6, or g.CLDN9 and r.CD81
(Fig. 2). There was limited evidence for an association between
g.CLDN12 and r.CD81 in a minority of cells, however the var-
iability of the data set and scatter of points around the line of
best fit suggest that, if present, this relationship is less well
defined (Table 1).
The FIR method gives an accurate measure of protein-pro-
tein association but is limited by the resolution of the micro-
scope. To demonstrate protein-protein interactions (within 10
nm) we measured FRET between CLDNs and CD81 using a
previously reported acceptor-photobleaching method (30).
FRET occurred between g.CLDN1, -6, and -9 and r.CD81 (60%,
50, and 63% of plasma membrane pixels, respectively) at a sig-
nificantly higher frequency than with other g.CLDNs (Table 1).
The level of g.CLDN or r.CD81 expression had no effect on
FRET (34) (supplemental Fig. S1). Because Occludin is also
important for HCV entry, we investigated the stoichiometry
and association of different CLDN molecules with Occludin.
Themajority ofCLDNs tested (CLDN1, -6, -9, -11, -12, and -17)
demonstrated amedian FIR with an IQR of between 0.6 and 0.9
(r2  0.2–0.5) with variable FRET, demonstrating no associa-
tion between CLDN receptor activity and ability to interact
with Occludin (Table 1). To ascertain whether CLDN1 could
associate with other CLDNswemeasured FIR and FRET values
in 293T cells transfected to express g.CLDN1, -4, -6, -7, or -9
FIGURE 2.Analysis of CLDN-CD81 interactions. 293T cells were transfected to express DsRED-CD81 (r.CD81)
and a panel of AcGFP-tagged CLDN (g.CLDN) constructs (CLDN1–17, panels A–I). Ten cells were imaged as
described in Fig. 1, and estimates of r.CD81 association with g.CLDNs were evaluated by regression analysis
and summarized in Table 1. The images represent scatter plots closest to the median FIR for each g.CLDN-
r.CD81 studied.
Receptor Complexes in HCV Entry
21096 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 27•JULY 2, 2010
 at The University of Birm
ingham
, on Septem
ber 24, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2010/04/07/M110.104836.DC1.html
Supplemental Material can be found at:
and r.CLDN1. Associations were detected between g.CLDNs 1, 4,
6, and9andr.CLDN1bybothFIRandFRETanalysis, demonstrat-
ing CLDN1 homotypic and heterotypic cis-interactions; in con-
trast there was no demonstrable association between g.CLDN7
and r.CLDN1 (Table 1). In summary, we observed a significant
relationship between the association of CLDN with CD81 and
HCV receptor activity, suggesting that a close physical association
between CLDN and CD81 is essential for HCV entry.
Analysis of CLDN1-CD81 Interactions by Surface Plasmon
Resonance—To independently assess CLDN1-CD81 protein
interactions, recombinant MBP-CLDN1 EC1 or MBP-CD81
EC2 proteins were immobilized onto a BIAcore sensor chip, as
detailed under “Experimental Procedures.” Homotypic CLDN1
and CD81 protein interactions were observed, with minimal
detection of either recombinant loop protein interacting with
MBP (Fig. 3, A and B). Importantly, MBP-CD81 EC2 demon-
strated a specific interaction with MBP-CLDN1 EC1 and min-
imal interaction with MBP or MBP-CLDN7 (Fig. 3C). These
data are consistentwith our FRET imaging-based data (Table 1)
and demonstrate a role for the EC loops in driving CLDN1-
CD81 protein interactions.
Perturbation of CLDN1-CD81 Association—Tetraspanin
protein interactions are known to be modulated by cholesterol
(42–44). Kapadia and colleagues (45) reported that HCV entry
is dependent on the cholesterol content of the host cell mem-
brane, however, the underlyingmechanismwas not defined. To
investigate the role of cholesterol in CLDN1-CD81 and CD81-
CD81 association, 293T cells co-expressing g.CLDN1-r.CD81
or g.CD81-r.CD81 were treated with MCD, a cyclic oligosac-
charide that depletes cholesterol from the plasma membrane
(46). Treatment with 10 mM MCD removed 50% of total
cholesterol and reduced g.CLDN1 localization at the plasma
membrane, leading to an altered g.CLDN1-r.CD81 FIR and
reduced FRET (from 50  1.7% to 35  9.5%) (supplemental
Fig. S3). In contrast, MCD had no detectable effect on CD81
expression at the plasma membrane or g.CD81-r.CD81 FIR.
However, the frequency of pixels where FRET occurred
between g.CD81 and r.CD81 was reduced, from 63%  5.0 to
55%  1.8 (supplemental Fig. S3). To further investigate the
effects of cholesterol, MCD-treated cells were incubated with
MCD-cholesterol complexes that restored cellular choles-
terol to 75% of the initial value. This treatment restored both
g.CLDN1-r.CD81 FIR or FRET and g.CD81-r.CD81 FRET val-
ues to pretreatment levels (supplemental Fig. S3). As previously
reported (44) we found thatMCD treatment reducedHCVcc-
cultured cells and HCVpp infection (data not shown). These
data demonstrate that CLDN1 localization at the plasmamem-
brane and its association with CD81 is cholesterol-dependent,
which may in part contribute to the reduced susceptibility of
MCD-treated hepatoma cells to HCV infection.
CD81 is a critical molecule defining HCV infection and
treatment of hepatoma cells with anti-CD81 mAbs inhibits
both recombinant HCV E2 bind-
ing (1, 2, 7–9) and virus infectivity
(reviewed in Ref. 47). However,
the one or more mechanisms by
which the antibodies neutralize
virus infectivity are not known.
We were interested in studying
the effect(s) of two HCV-neutral-
izing anti-CD81 mAbs on CD81
homotypic and heterotypic protein-
protein interactions. 293T cells
co-expressing g.CD81-r.CD81 or
g.CLDN1-r.CD81 were treated with
mAbs 2s20 and 2s66 specific for
CD81 large extracellular loop or a
control mAb specific for vascular
adhesion protein 1. BothCD81-spe-
cific mAbs significantly reduced
g.CLDN1-r.CD81 FIR and FRET
FIGURE 3. Analysis of CLDN1-CD81 extracellular loop interactions by surface plasmon resonance.MBP-
CLDN1 EC1 (A) and MBP-CD81 EC2 (B and C) were immobilized onto the bio-sensor chip surface. Homotypic
protein interactions were demonstrated by flowingMBP-CLDN1 EC1 (solid gray line) andMBP-CD81 EC2 (solid
black line) over the respective chip surfaces (A andB)withbothMBP-CLDN7EC1 (dotted light gray line) andMBP
(dotted black line) as negative controls at a concentration of 1 mg/ml. Heterotypic interaction between MBP-
CLDN1-EC1 andMBP-CD81 EC2 is depicted in C. To control for nonspecific interactions, all MBP fusion proteins
were flowed over an activated and blocked “empty” channel, and the response unit(s) were subtracted from
the test channels. The arrow indicates the “association time” i when proteins are flowed over the respective
chip surfaces and the “dissociation phase” begins at time iiwhen protein injection is stopped. Data are repre-
sentative of two independent experiments.
TABLE 1
Fluorescence-tagged CLDN protein association with CD81, Occludin,
and CLDN1
r2 (IQR)a FIR (IQR) %FRET S.D.b
CD81 association with
CLDN1 0.5 (0.42–0.61) 0.7 (0.67–0.74) 60 4
CLDN4 0.2 (0.17–0.24) 0.3 (0.21–0.41) 5 8
CLDN6 0.6 (0.54–0.62) 1.0 (0.80–1.10) 50 6
CLDN7 0.0 (0.00–0.09) NDc ND
CLDN9 0.4 (0.36–0.50) 0.5 (0.40–0.67) 63 7
CLDN11 0.2 (0.16–0.23) 0.3 (0.19–0.41) 7 4
CLDN12 0.4 (0.28–0.48) 0.5 (0.26–0.83) 15 12
CLDN15 0.0 (0.00–0.04) ND ND
CLDN17 0.2 (0.17–0.30) 0.3 (0.22–0.52) 6 8
Occludin association with
CLDN1 0.4 (0.29–0.54) 0.7 (0.60–0.82) 48 1
CLDN4 0.2 (0.14–0.34) 0.3 (0.29–0.53) 30 7
CLDN6 0.2 (0.04–0.36) 0.8 (0.57–0.53) 27 9
CLDN7 0.1 (0.04–0.18) ND ND
CLDN9 0.3 (0.13–0.48) 0.7 (0.39–0.79) 18 8
CLDN11 0.4 (0.12–0.45) 0.7 (0.62–0.83) 23 7
CLDN12 0.3 (0.19–0.37) 0.6 (0.51–0.71) 38 6
CLDN15 0.1 (0.08–0.21) ND ND
CLDN17 0.5 (0.28–0.51) 0.9 (0.74–1.07) 40 5
CLDN1 association with
CLDN1 0.7 (0.67–0.74) 0.5 (0.43–0.58) 41 4
CLDN4 0.3 (0.22–0.41) 0.2 (0.18–0.24) 18 12
CLDN6 1.0 (0.82–1.11) 0.6 (0.51–0.59) 31 6
CLDN7 0.1 (0.00–0.10) ND ND
CLDN9 0.4 (0.36–0.42) 0.5 (0.44–0.63) 18 3
a Interquartile range.
b Standard deviation.
cND, not determined.
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values and yet hadminimal effect(s) on g.CD81/r.CD81 FIR and
FRET (Fig. 4). In contrast, anti-vascular adhesion protein 1 had
no effect on g.CD81-r.CD81 or g.CLDN1-r.CD81 FIR/FRET
values (Fig. 4). To investigate
whether bivalent engagement of
CD81 is critical to modulate lateral
protein-protein interactions, we
studied the effect of monovalent
2s66 FAb fragment on g.CD81-
r.CD81 and g.CLDN1-r.CD81 FIR.
Although 2s66 FAb bound to CD81
LEL with a similar affinity to the
complete IgG molecule, it had no
detectable effect on g.CD81-r.CD81
or g.CLDN1-r.CD81 FIR or FRET
values (Fig. 4), suggesting that biva-
lent engagement and possible cross-
linking of CD81 are essential to
modulate lateral protein interac-
tions. Of note, 5-fold increased con-
centrations of 2s66 FAb were
required to neutralize HCV infec-
tivity compared with the bivalent
2s66 IgG (IC50 values for 2s66 IgG
are 0.8Mand 2s66 FAb are 4.3M).
Because CD81 is known to associ-
ate with tetraspanin CD9, we
assessed the ability of anti-CD9
mAb TS9 to influence CD81 pro-
tein associations. Anti-CD9 TS9
bound to 293T cells but had no
detectable effect on g.CD81-r.CD81
or g.CLDN1-r.CD81 FIR or FRET
values, consistent with its inability
to inhibit HCV entry (Fig. 4). In
summary, bivalent antibody en-
gagement of CD81 perturbs protein
interactions with CLDN1 and may
contribute to the neutralizing activ-
ity of these mAbs.
Mutations inCLDNEC1Modulate
CD81 Interaction(s) and HCV Recep-
tor Activity—CLDN1 and CLDN7
differ in five residues within their first
extracellular loop, and Evans and
colleagues reported that the inter-
change of amino acid residues at
positions 32 (Ile/Met) and 48 (Glu/
Lys) rendered CLDN1 inactive and
CLDN7 active for infection by
unknown mechanism(s) (14). We
hypothesized that these residues
could play a role in the association
of CLDN1 with CD81. To evaluate
this 293T cells were co-transfected
with plasmids expressing r.CD81 or
r.Occludin with either g.CLDN1,
g.CLDN1-I32M, g.CLDN1-E48K,
g.CLDN1-I32M/E48K, g.CLDN7, g.CLDN7-M32I, g.CLDN7-
K48E, or g.CLDN7-M32I/K48E (Fig. 5). Confocal imaging
demonstrated that all proteins were expressed at comparable
FIGURE 4. Anti-CD81 modulation of CD81-CD81 and CLDN1-CD81 association(s). 293T cells were trans-
fected to express AcGFP (g) and DsRED (r) fluorescence-tagged g.CD81-r.CD81 or g.CLDN1-r.CD81 and were
treated with control anti-VAP1, anti-CD81 mAbs 2s20 and 2s66, 2s66 FAb fragment, and anti-CD9 TS9 at
equimolar concentrations (13 M) for 1 h at 37 °C. Representative g.CD81-r.CD81 and g.CLDN1-r.CD81 scatter
plots of transfected cells treatedwith anti-VAP-1, anti-CD812s66 IgG, and FAbare shown (A). The effect ofmAb
treatments on g.CD81-r.CD81 (B) and g.CLDN1-r.CD81 (C) mean correlation coefficient (r2) and fluorescent
intensity ratio (FIR) of ten cells is presented. One way analysis of variance and Dunnett’s multiple comparison
test were used to determine the degree of significance (*, p 0.05; **, p 0.01).
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levels at the plasmamembrane (data not shown).Analysis of the
panel of g.CLDNs for their association(s)with r.CD81 and r.Oc-
cludin was performed by both FIR and FRET methodologies.
g.CLDN1 and g.CLDN7 wild-type proteins showed the
expected high and low FIR values with CD81 and Occludin, as
previously observed (Table 1). Interestingly, the two mutations
in CLDN1 (32M and 48K), either alone or in combination,
abrogated any association with CD81 or Occludin. In contrast,
both of the complementary changes in CLDN7 (32I and 48K)
resulted in amutated CLDN7molecule that showed clear asso-
ciation with CD81 (16 and 25% FRET for 32I and 48E, respec-
tively), and this was even more marked in the double mutant
CLDN7 whose levels of association with CD81 were indistin-
guishable from that of CLDN1 (Fig. 5). Neither of themutations
promoted CLDN7 association with Occludin, suggesting that
CLDN-Occludin interactions are not required for CLDN
receptor activity. When tested for their susceptibility to infec-
tion these cells recapitulated knownphenotypes (14), where the
single and double mutation in CLDN1 abrogated HCVpp entry
andCLDN7mutants showed 36% (M32I), 41% (E48K), and 47%
(double mutant) of the infectivity signal obtained for g.CLDN1
(supplemental Fig. S4).
To assess whether the mutations in CLDN1 and CLDN7,
which modulate CD81 association, alter CLDN-CLDN homo-
typic interactions, 293T cells were co-transfected with AcGFP-
and DsRED-tagged versions of parental and mutant CLDNs
FIGURE 5. Effect ofmutations in CLDN1andCLDN7EC1onCD81 andOccludin association. 293T cells were transfected to express AcGFP (g) andDsRED (r)
fluorescence-tagged wild-type and mutant forms of g.CLDN and r.CD81 (A) or r.Occludin (B), and the degree of association between fluorophore-tagged
proteins was assessed by FIR and FRET analysis. C, 293T cells were transfected with AcGFP- and DsRED-tagged versions of wild-type and mutant CLDN
constructs to assess the effect of EC1mutations onCLDN-CLDNcis-interactions.Median FIR and FRET values from ten individual cells are presented (*,p 0.05;
**, p 0.01).
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and assessed by FIR and FRET analysis (Fig. 5C). As noted earlier
(Fig. 1C), parental CLDN1 molecules associated with each other
(Fig. 5C), however, when either of the residues at codons 32 or 48
werechanged, therewasamodestbutnon-significant reduction in
FIR, suggesting that these residues have aminor role in the genesis
or stabilization of CLDN1 dimers. In contrast neither of the alter-
ations inCLDN7altered the degree of homotypic association (Fig.
5C). Thus, we infer that it is the heterotypic interaction between
CLDNs and CD81, rather than the homotypic CLDN-CLDN
interactions, that is important for HCV entry.
The Effect(s) of Cell Polarization on CD81-CLDN1 Asso-
ciation—293T cells do not polarize or form functional tight
junctions; we therefore sought to confirm our observations on
CLDN1-CD81 association in a polarized cell type. This is par-
ticularly relevant to our understanding of HCV infection,
because hepatocytes, themajor target cell supportingHCV rep-
lication in the liver, are highly polarized (48). The human
HepG2 hepatoblastoma line has been shown to polarize in cul-
ture, forming spheroid structures at sites of cell-cell contact
that contain tight junctions and multiple membrane protein
markers that resemble bile canaliculi in the liver (reviewed in
Ref. 48) (Fig. 6A). HepG2 cells were transduced to express
g.CLDN1-r.CLDN1 or g.CLDN1-r.CD81 and allowed to prolif-
erate for 72 h, whereupon polarized cells were identified by
staining for the apical tight junctionmarker ZO-1 (Fig. 6A) (33).
g.CLDN1-r.CLDN1 at the basolateral membrane associated
with a median FIR of 0.67 (r2  0.36) (Fig. 6), comparable
to the values observed in 293T cells. Similar observations
were made for g.CLDN1-r.CLDN1
at tight junctions demonstrating a
median FIR of 0.56 (r2 0.28) (Fig.
6). FRET between g.CLDN1-
r.CLDN1 at basolateral and tight
junctions, 36 and 10%, respectively,
occurred at a lower frequency than
that observed in 293T cells, most
likely reflecting the presence of
endogenous CLDN1 in HepG2 cells
that may compete for CD81 and
CLDN1 association(s) (30). Basolat-
eral membrane pools of g.CLDN1-
r.CD81 demonstrated a median FIR
of 0.7 (r2 0.7) and 25% FRET (Fig.
6). In contrast, r.CD81 was largely
excluded from tight junctions with
no detectable CLDN1-CD81 com-
plexes (r2  0.1 and 1% FRET)
(Fig. 6). In summary, CLDN1 dem-
onstrated comparable association(s)
with CLDN1 at basolateral and
tight junction membranes in polar-
ized HepG2 cells, similar to our
observations in non-polarized 293T
cells. In contrast, significant differ-
ences were noted for g.CLDN1-
r.CD81 association at the basolat-
eral and tight junction domains of
HepG2 cells, withminimal evidence
for complex formation at the tight junction. These data are
consistent with our previous report demonstrating a role for
basolateral pools of CLDN1 in HCV infection (33).
DISCUSSION
HCV entry into host cells is most likely to occur through a
multistep process. Current evidence suggests that scavenger
receptor class B member I may define the attachment of HCV
virolipoparticles to the cell surface, and this may prime particle
interaction(s) with CD81 and Claudin co-receptors that are
essential for subsequent particle internalization events (49, 50).
In the present study we demonstrate a relationship between
receptor-active CLDNs and their association and organization
with CD81 at the plasmamembrane. Given the reported role of
Occludin in HCV entry, we investigated the stoichiometry and
FRET between CLDN proteins and Occludin. The majority of
CLDN proteins interacted with Occludin, and there was no
discernable relationship between CLDN receptor activity and
ability to associate with Occludin (Table 1). Mutation of resi-
dues 32 and 48 in CLDN1 EC1 ablated CD81 and Occludin
association and HCV receptor activity (Fig. 5), which may
reflect an altered EC1 conformation. Importantly, mutation of
the same residues in CLDN7 enabled CD81 complex formation
and virus entry without any detectable Occludin association,
demonstrating an essential role of CLDN-CD81 receptor com-
plexes in HCV infection.
TaggingCLDNproteinswithAcGFPorDsREDenabled us to
assess protein localization in the absence of CLDN-specific
FIGURE 6. Effect of cell polarization on CLDN1-CD81 and CLDN1-CLDN1 association. HepG2 cells trans-
fected to express AcGFP (g) and DsRED (r) fluorescence-tagged g.CLDN-r.CD81 and g.CLDN1-r.CLDN1 were
allowed to polarize over a period of 3 days. Apical bile canalicular structures were identified by staining with
anti-ZO-1 and visualized with alexa-633-conjugated secondary anti-rabbit Ig (A). Representative scatter plots
of g.CLDN-r.CD81 and g.CLDN1-r.CLDN1 at basolateral (B) and tight junction (C) membrane domains are
shown, and the cumulative data from ten cells are summarized below (D).
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mAbs. The majority of AcGFP-tagged CLDNs localized to
the plasma membrane, with only CLDN15 showing a domi-
nant intracellular staining pattern. As viral receptor activity is
dependent on cell surface expression (51), the inability of
CLDN4, -7, -11, -12, and -17 to mediate HCVpp entry is
unlikely to be ascribed to low expression levels. The observa-
tion that only receptor-active CLDNs associate with CD81 (Fig.
2) provides supporting evidence for a role for these protein
complexes in the HCV entry process.
CLDNs oligomerize to form tight junction strands, and sev-
eral reports demonstrate homotypic and heterotypic interac-
tions between different members of the CLDN family (52–54).
FIR and FRET analysis demonstrated interactions between
CLDN1 and CLDNs 4, 6, and 9 in 293T cells (Table 1). In con-
trast there was no significant association between CLDN1 and
CLDN7 (r2 0.11) (Table 1). These data are supported by sur-
face plasmon resonance data showing CLDN1 EC1-EC1 inter-
action in the absence of any significant association between
CLDN1 and CLDN7 EC1 regions (Fig. 3). It was interesting to
note that overexpression of non-receptor CLDNs with
g.CLDN1 in 293T cells hadminimal effects onCLDN1-CLDN1
association or HCV entry (data not shown). Mutation of resi-
dues 32 and 48 in EC1 ofCLDN1 andCLDN7had no significant
effects on homotypic cis-interactions (Fig. 5), consistent with a
recent report that residues in the EC2 of CLDN5 define homo-
typic cis-interactions (28). We hypothesize that CLDN1 may
associate with both CD81 and CLDN1 via interactions through
its EC1 and EC2 loops, respectively, suggesting the presence of
receptor heterodimers.
Anti-CD81 mAbs 2s20 and 2s66 reduced CLDN1-CD81 FIR
and FRET values and yet had minimal impact on CD81-CD81
association (Fig. 4), reflecting potential differences in protein
conformation or temporal association of CD81-CD81 and
CLDN1-CD81 complexes. 2s66 FAb had a minimal effect on
CLDN1-CD81 association, despite showing a comparable Kd
for recombinant CD81 LEL to the complete IgGmolecule (2s66
IgG Kd 1.7E07; 2s66 FAb Kd 8.6E06), suggesting that biva-
lent cross-linking of CD81 may be necessary to perturb CD81
association with CLDN1. It is interesting to note that 2s66 FAb
demonstrated a 5-fold reduced capacity to neutralize HCV
infection compared with 2s66 IgG, suggesting that antibody-
induced disruption of CLDN1-CD81 complexes may contrib-
ute to the neutralizing activity of anti-CD81 antibodies.
To investigate whether CLDN association with CD81 is crit-
ical for viral receptor activity we investigated the effect of
known receptor inactivating mutations in CLDN1 EC1 on pro-
tein association with CD81.We selected two previously identi-
fied amino acids (residues 32 and 48) in EC1, where the recip-
rocal interchange between CLDN1 and CLDN7 sequences
abrogated receptor activity of CLDN1 and conferred receptor
activity to CLDN7 by unknown mechanism(s) (14). Neither
mutation had an effect onCLDN1/CLDN7 expression or trans-
port to the cell surface, consistent with a recent report by Cuik-
erman and colleagues demonstrating that alanine substitution
at residue 32 ablated receptor activity with minimal perturba-
tion of protein localization (32). In contrast Liu and colleagues
reported that CLDN1 I32M was not expressed at the cell sur-
face (19). These differences may reflect the use of different vec-
tors to express CLDN1 in the various studies, because we
and others have noted that high level expression of CLDNs
can lead to their intracellular accumulation (30, 32). Impor-
tantly, we found that introduction of both mutations in
CLDN1destroyed lateral associationswithCD81, whereas sub-
stitution of both residues in CLDN7 promoted heterotypic
association with CD81 (Fig. 5A). In contrast, mutation of both
residues in CLDN1 or CLDN7 had amodest to negligible effect
on homotypic cis-associations (Fig. 5C), respectively, demon-
strating a critical role for CLDN-CD81 complexes in HCV
entry.
The major reservoir supporting HCV replication in vivo is
thought to be hepatocytes in the liver. Hepatocytes polarize
with at least two basal surfaces facing the circulation and a
branched network of grooves between adjacent cells that con-
stitute the apical or bile canalicular surface (55). Tight junction
strands encircle the apical region and comprise multiple trans-
membrane, scaffolding, and signaling proteins (reviewed in Ref.
56).We recently reportedCLDN1 expression at basolateral and
apical hepatocyte membranes in normal liver tissue (57) and in
polarized HepG2 cells, with an enrichment at tight junction-
associated apical sites (33). To extend our studies on CLDN1-
CD81 association in 293T cells and to investigate the presence
and location of receptor complexes in polarized HepG2 cells,
we transduced HepG2 cells to stably express AcGFP- and
DsRED-tagged versions of CLDN1 and CD81. Overexpression
of either molecule had no effect on the polarization of HepG2
cells (data not shown). CLDN1 was found to associate with
basolateral pools of CLDN1 and CD81 with reduced FRET val-
ues (36 and 25%, respectively) compared with 293T cells, most
likely representing competition from endogenous CLDNs,
as previously reported (30). In contrast, CD81 was largely
excluded from the tight junction and exhibited a minimal asso-
ciation with CLDN1 (Fig. 6).
HCV enters the liver via the sinusoidal blood, and therefore
the virus will encounter receptors expressed on the sinusoidal
or basal surface of the hepatocyte. Our current data, showing
that CLDN1 receptor activity correlates with the formation of
CLDN1-CD81 complexes that localize at the basolateral sur-
face of polarized hepatoma cells, support a model where virus
engagement of CD81-CLDN1 at the basal membrane may ini-
tiate the particle internalization process (33). The role ofOcclu-
din in HCV entry into polarized cells is poorly defined. Our
current data fail to demonstrate a role for CLDN-Occludin
complexes in HCV infection. HCV internalizes via a clathrin-
dependent process and fusion is believed to occur within the
early endosomes (49, 50, 58). At present it is unknown whether
any of the viral receptors, including CD81 and CLDN1, are
endocytosed with HCV, and further research on the trafficking
and endocytic routing of receptor complexes and virus particles
in polarized hepatocytes is required to fully appreciate the com-
plex entry process of HCV in the liver.
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